368 related articles for article (PubMed ID: 25519927)
1. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Cooper AB; Slack R; Fogelman D; Holmes HM; Petzel M; Parker N; Balachandran A; Garg N; Ngo-Huang A; Varadhachary G; Evans DB; Lee JE; Aloia T; Conrad C; Vauthey JN; Fleming JB; Katz MH
Ann Surg Oncol; 2015 Jul; 22(7):2416-23. PubMed ID: 25519927
[TBL] [Abstract][Full Text] [Related]
2. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Tzeng CW; Fleming JB; Lee JE; Xiao L; Pisters PW; Vauthey JN; Abdalla EK; Wolff RA; Varadhachary GR; Fogelman DR; Crane CH; Balachandran A; Katz MH
Ann Surg Oncol; 2012 Jun; 19(6):2045-53. PubMed ID: 22258816
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
5. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
6. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Golcher H; Brunner TB; Witzigmann H; Marti L; Bechstein WO; Bruns C; Jungnickel H; Schreiber S; Grabenbauer GG; Meyer T; Merkel S; Fietkau R; Hohenberger W
Strahlenther Onkol; 2015 Jan; 191(1):7-16. PubMed ID: 25252602
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
14. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
[TBL] [Abstract][Full Text] [Related]
16. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
[TBL] [Abstract][Full Text] [Related]
17. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
18. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
[TBL] [Abstract][Full Text] [Related]
19. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]